|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027651,
umls-concept:C0039194,
umls-concept:C0085358,
umls-concept:C0205251,
umls-concept:C0205263,
umls-concept:C0254610,
umls-concept:C0338106,
umls-concept:C0441889,
umls-concept:C0683201,
umls-concept:C0872192,
umls-concept:C1327616,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1706438,
umls-concept:C2698600
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-9-17
|
|
pubmed:abstractText |
Although interleukin (IL)-15 augments innate and acquired immunities, IL-15 expression is controlled at the levels of transcription, translation and intracellular trafficking. We constructed plasmid vectors encoding the murine mature-IL-15 cDNA linked to an Igkappa leader sequence and full-length murine IL-15 cDNA to evaluate the efficacy of the mature-IL-15 vector. Weakly immunogenic colon 26 cells were transfected with the above-mentioned vectors or with empty vector (mock). Transfectants with mature-IL-15 produced significantly higher levels of IL-15 than did transfectants with full-length IL-15. When injected into syngeneic BALB/c mice, transfectants secreting high levels of IL-15 were rejected completely. Depletion of natural killer cells or CD4+ T cells did not affect the growth of transfectants. In contrast, transfectants treated with anti-CD8 antibody re-grew 1 month later after implantation. These findings indicate that CD8+ T cells are required for complete rejection of the tumor. Gene therapy with transfectants expressing mature-IL-15 containing the Igkappa leader sequence may be useful as a tumor vaccine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1107-3756
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
571-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15375583-Animals,
pubmed-meshheading:15375583-Antigens, CD4,
pubmed-meshheading:15375583-Antigens, CD8,
pubmed-meshheading:15375583-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15375583-Cancer Vaccines,
pubmed-meshheading:15375583-Cell Line, Tumor,
pubmed-meshheading:15375583-Cell Proliferation,
pubmed-meshheading:15375583-Colonic Neoplasms,
pubmed-meshheading:15375583-Female,
pubmed-meshheading:15375583-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15375583-Genetic Vectors,
pubmed-meshheading:15375583-Immunohistochemistry,
pubmed-meshheading:15375583-Interleukin-15,
pubmed-meshheading:15375583-Killer Cells, Natural,
pubmed-meshheading:15375583-Mice,
pubmed-meshheading:15375583-Mice, Inbred BALB C,
pubmed-meshheading:15375583-Neoplasm Transplantation,
pubmed-meshheading:15375583-RNA, Messenger,
pubmed-meshheading:15375583-Transfection
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Tumor secreting high levels of IL-15 induces specific immunity to low immunogenic colon adenocarcinoma via CD8+ T cells.
|
|
pubmed:affiliation |
Department of Surgery II, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
